Pharmacology & Therapeutics / Sep 01, 2018

Baretti, M., & Le, D. T. (2018). DNA mismatch repair in cancer. Pharmacology & Therapeutics, 189, 45–62. https://doi.org/10.1016/j.pharmthera.2018.04.004

Nature Reviews Cancer / Aug 27, 2019

Reiter, J. G., Baretti, M., Gerold, J. M., Makohon-Moore, A. P., Daud, A., Iacobuzio-Donahue, C. A., Azad, N. S., Kinzler, K. W., Nowak, M. A., & Vogelstein, B. (2019). An analysis of genetic heterogeneity in untreated cancers. Nature Reviews Cancer, 19(11), 639–650. https://doi.org/10.1038/s41568-019-0185-x

Immunotherapy / Jul 01, 2020

Rossi, S., Toschi, L., Finocchiaro, G., & Santoro, A. (2020). Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy, 12(10), 715–724. https://doi.org/10.2217/imt-2019-0154

Digestive and Liver Disease / Oct 01, 2015

Sefrioui, D., Sarafan-Vasseur, N., Beaussire, L., Baretti, M., Gangloff, A., Blanchard, F., Clatot, F., Sabourin, J.-C., Sesboüé, R., Frebourg, T., Michel, P., & Di Fiore, F. (2015). Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Digestive and Liver Disease, 47(10), 884–890. https://doi.org/10.1016/j.dld.2015.05.023

Current Problems in Cancer / Nov 01, 2018

Baretti, M., & Azad, N. S. (2018). The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer, 42(6), 530–547. https://doi.org/10.1016/j.currproblcancer.2018.03.001

Annals of Oncology / Mar 01, 2017

Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., … Cremolini, C. (2017). Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 28(3), 555–561. https://doi.org/10.1093/annonc/mdw627

Cancer Medicine / Dec 29, 2015

Ghidini, M., Personeni, N., Bozzarelli, S., Baretti, M., Basso, G., Bianchi, P., Tronconi, M. C., Pressiani, T., Grizzi, F., Giordano, L., Malesci, A., Alloisio, M., Laghi, L., Santoro, A., & Rimassa, L. (2015). <scp>KRAS</scp> mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 5(2), 256–264. Portico. https://doi.org/10.1002/cam4.592

Immunotherapy / Dec 01, 2016

Simonelli, M., Di Tommaso, L., Baretti, M., & Santoro, A. (2016). Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy, 8(12), 1363–1369. https://doi.org/10.2217/imt-2016-0057

JCO Precision Oncology / Jun 01, 2022

Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khouiery, A. B., Hockenberry, A. J., Lau, D., Lesinski, G. B., & Yarchoan, M. (2022). Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00510

Journal of Clinical Investigation / Aug 16, 2021

Baretti, M., & Yarchoan, M. (2021). Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. Journal of Clinical Investigation, 131(16). https://doi.org/10.1172/jci151002

Annals of Pancreatic Cancer / Oct 01, 2019

Baretti, M., Ahuja, N., & Azad, N. S. (2019). Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. Annals of Pancreatic Cancer, 2, 18–18. https://doi.org/10.21037/apc.2019.10.01

Pancreas / May 01, 2021

Baretti, M., Zhu, Q., Zahurak, M., Bhaijee, F., Xu, H., Engle, E. L., Kotte, A., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2021). Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas, 50(5), 719–726. https://doi.org/10.1097/mpa.0000000000001831

Journal of Clinical Oncology / May 20, 2018

Baretti, M., Durham, J. N., Walker, R., Mitcheltree, A.-L., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2018). Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. Journal of Clinical Oncology, 36(15_suppl), TPS4151–TPS4151. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4151

Hepatology / Aug 21, 2021

Solipuram, V., Baretti, M., Kim, A. Y., Chen, L. X., Fahrner, J. A., Gunay‐Aygun, M., Peng, X. P., Hardenbergh, D., Ferguson, A., Griffith, P., Wang, Y., Brancati, M., Gopalakrishna, H., Kato, T., Shubert, C., Laheru, D., & Yarchoan, M. (2021). Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma. Hepatology, 74(5), 2899–2901. https://doi.org/10.1002/hep.31998

Cancer Control / Jan 01, 2021

Jia, A. Y., Popovic, A., Mohan, A. A., Zorzi, J., Griffith, P., Kim, A. K., Anders, R. A., Burkhart, R. A., Lafaro, K., Georgiades, C., Azad, N. S., Liddell, R. P., Baretti, M., Kamel, I. R., Narang, A., Yarchoan, M., & Meyer, J. (2021). Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 28, 107327482110099. https://doi.org/10.1177/10732748211009945

OncoImmunology / Jan 01, 2021

Delitto, D., Zabransky, D. J., Chen, F., Thompson, E. D., Zimmerman, J. W., Armstrong, T. D., Leatherman, J. M., Suri, R., Lopez-Vidal, T. Y., Huff, A. L., Lyman, M. R., Guinn, S. R., Baretti, M., Kagohara, L. T., Ho, W. J., Azad, N. S., Burns, W. R., He, J., Wolfgang, C. L., … Jaffee, E. M. (2021). Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. OncoImmunology, 10(1). https://doi.org/10.1080/2162402x.2021.2001159

Cancer Cell / Mar 01, 2022

Baretti, M., Kim, A. K., & Anders, R. A. (2022). Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 40(3), 252–254. https://doi.org/10.1016/j.ccell.2022.02.017

Clinical and Translational Science / Apr 03, 2021

Baretti, M., Karunasena, E., Zahurak, M., Walker, R., Zhao, Y., Pisanic, T. R., Wang, T., Greten, T. F., Duffy, A. G., Gootjes, E., Meijer, G., Verheul, H. M. W., Ahuja, N., Herman, J. G., & Azad, N. S. (2021). A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science, 14(3), 954–963. Portico. https://doi.org/10.1111/cts.12960

The Cancer Journal / Jul 01, 2019

Baretti, M., & Azad, N. S. (2019). Precision Cancer Trials With Immunomodulatory Agents. The Cancer Journal, 25(4), 287–295. https://doi.org/10.1097/ppo.0000000000000390

Annals of Oncology / Oct 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of Oncology, 27, vi233. https://doi.org/10.1093/annonc/mdw371.84

Annals of Oncology / Sep 01, 2014

Sefrioui, D., Vasseur, C., Sesboué, R., Blanchard, F., Gangloff, A., Baretti, M., Beaussire, L., Clatot, F., Dolfus, C., Sabourin, J., Michel, P., Frebourg, T., & Di Fiore, F. (2014). Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer. Annals of Oncology, 25, iv559. https://doi.org/10.1093/annonc/mdu358.48

Annals of Oncology / Sep 01, 2012

Ginocchi, L., Vasile, E., Caponi, S., Lucchesi, M., Caparello, C., Da Prat, V., Baretti, M., Lencioni, M., Ricci, S., & Falcone, A. (2012). Modified Folfoxiri in advanced Pancreatic Cancer. Annals of Oncology, 23, ix238. https://doi.org/10.1016/s0923-7534(20)33292-0

Annals of Oncology / Sep 01, 2012

Borad, M., Reddy, S., Bahary, N., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W., Stephenson, J., Eng, C., & Ryan, D. P. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, 23, ix224. https://doi.org/10.1093/annonc/mds398

Annals of Surgery Open / Oct 03, 2022

Li, D., Jia, A. Y., Zorzi, J., Griffith, P., Kim, A. K., Dao, D., Anders, R. A., Georgiades, C., Liddell, R. P., Hong, K., Azad, N. S., Ho, W. J., Baretti, M., Christenson, E., Baghdadi, A., Kamel, I. R., Meyer, J., Ghabi, E., Burkhart, R. A., … Yarchoan, M. (2022). Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer Clinic. Annals of Surgery Open, 3(4), e207. https://doi.org/10.1097/as9.0000000000000207

Cancers / Oct 30, 2022

Chen, K. Y., Popovic, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., & Yarchoan, M. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 14(21), 5347. https://doi.org/10.3390/cancers14215347

Annals of Oncology / Sep 01, 2021

Heumann, T. R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T. Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C. D., O’Dwyer, P. J., Monga, D. K., Reiss Binder, K. A., & Azad, N. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology, 32, S1087–S1088. https://doi.org/10.1016/j.annonc.2021.08.797

Mayo Clinic Proceedings / May 01, 2021

Smith, T. J., Ferguson, A., Baretti, M., & Yarchoan, M. (2021). Successful Treatment With Scrambler Therapy for Radial and Femoral Nerve Injuries After Extracorporeal Membrane Oxygenation. Mayo Clinic Proceedings, 96(5), 1374–1375. https://doi.org/10.1016/j.mayocp.2021.03.025

HepatoBiliary Surgery and Nutrition / Mar 01, 2019

Baretti, M., Walker, R., Durham, J., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2019). AB049. P-17. A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced cholangiocarcinoma. HepatoBiliary Surgery and Nutrition, 8(S1), AB049–AB049. https://doi.org/10.21037/hbsn.2019.ab049

Annals of Oncology / Sep 01, 2017

Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Morano, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., Miceli, R., & Aprile, G. (2017). Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Annals of Oncology, 28, v227. https://doi.org/10.1093/annonc/mdx369.052

Annals of Oncology / Oct 01, 2015

Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M. C., De Sanctis, R. M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology, 26, vi150. https://doi.org/10.1093/annonc/mdv348.59

Cancer Research / Apr 04, 2023

Kamdar, Z., Lopez-Vidal, T., Howe, K., Munjal, K., Saeed, A., Zabransky, D., Shu, D., Longway, G., Kartalia, E., Leatherman, J., Mohan, A., Khare, P., Zhang, C., Le, A., Pearce, E., Furth, M., Baretti, M., Leone, R., Jaffee, E., & Yarchoan, M. (2023). Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment. Cancer Research, 83(7_Supplement), 3679–3679. https://doi.org/10.1158/1538-7445.am2023-3679

Clinical Epigenetics / Dec 01, 2022

Heumann, T. R., Baretti, M., Sugar, E. A., Durham, J. N., Linden, S., Lopez-Vidal, T. Y., Leatherman, J., Cope, L., Sharma, A., Weekes, C. D., O’Dwyer, P. J., Reiss, K. A., Monga, D. K., Ahuja, N., & Azad, N. S. (2022). A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics, 14(1). https://doi.org/10.1186/s13148-022-01367-8

Epigenetics and DNA Damage / Jan 01, 2022

Baretti, M., & Azad, N. S. (2022). Epigenetic therapy and DNA damage response. Epigenetics and DNA Damage, 227–252. https://doi.org/10.1016/b978-0-323-91081-1.00009-1

Oncotarget / Jul 28, 2022

Baretti, M., Zhu, Q., Fu, W., Meyer, J., Wang, H., Anders, R. A., & Azad, N. S. (2022). Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. Oncotarget, 13(1), 907–917. https://doi.org/10.18632/oncotarget.28255

Annals of Oncology / Oct 01, 2019

De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M. L., Alonso, V., Riesco Martinez, M. C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., & Viudez, A. (2019). SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Annals of Oncology, 30, v196. https://doi.org/10.1093/annonc/mdz245.006

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Fu, W., Wang, H., Anders, R. A., Azad, N. S., & Zhu, Q. (2019). Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer. Journal of Clinical Oncology, 37(4_suppl), 570–570. https://doi.org/10.1200/jco.2019.37.4_suppl.570

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Zhu, Q., Zahurak, M., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2019). The impact of the immune microenvironment in patients with GEP-NETs. Journal of Clinical Oncology, 37(4_suppl), 267–267. https://doi.org/10.1200/jco.2019.37.4_suppl.267

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

Journal of Thoracic Oncology / Jan 01, 2017

Mountzios, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., Toschi, L., & Metro, G. (2017). P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice. Journal of Thoracic Oncology, 12(1), S706–S707. https://doi.org/10.1016/j.jtho.2016.11.930

Annals of Oncology / Oct 01, 2016

Baretti, M., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Rimassa, L., & Santoro, A. (2016). Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Annals of Oncology, 27, vi183. https://doi.org/10.1093/annonc/mdw370.104

Annals of Oncology / Sep 01, 2016

Baretti, M., Giordano, L., Rimassa, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Personeni, N., & Santoro, A. (2016). Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Annals of Oncology, 27, iv48. https://doi.org/10.1093/annonc/mdw335.29

Annals of Oncology / Sep 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort. Annals of Oncology, 27, iv25. https://doi.org/10.1093/annonc/mdw333.29

Annals of Oncology / Sep 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience. Annals of Oncology, 27, iv18. https://doi.org/10.1093/annonc/mdw333.03

Annals of Oncology / Jun 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer. Annals of Oncology, 27, ii51. https://doi.org/10.1093/annonc/mdw199.167

Annals of Oncology / Jun 01, 2016

Pietrantonio, F., Cremolini, C., Rimassa, L., Lonardi, S., Mennitto, A., Morano, F., Iacono, D., Berenato, R., Caporale, M., Niger, M., Marmorino, F., Bozzarelli, S., Bergamo, F., Rossini, D., Baretti, M., Battaglin, F., Bonotto, M., Loupakis, F., de Braud, F., & Miceli, R. (2016). O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 27, ii122. https://doi.org/10.1093/annonc/mdw198.13

Revista de Direitos e Garantias Fundamentais / Aug 06, 2012

Pinho, H. D. B. de, & Paumgartten, M. P. (2012). L’esperienza italo-brasiliana nell’uso della mediazione in risposta alla crisi del monopolio statale di soluzione di conflitti e la garanzia di acceso alla giustizia. Revista de Direitos e Garantias Fundamentais, 11, 171. https://doi.org/10.18759/rdgf.v0i11.178

Annals of Oncology / Sep 01, 2012

Caparello, C., Vasile, E., Lencioni, M., Fabrini, M. G., Lucchesi, M., Ginocchi, L., Caponi, S., Santi, S., Ricci, S., & Falcone, A. (2012). Third-Line Folfiri in Metastatic Gastric Cancer Patients. Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33344-5

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Journal of Clinical Oncology / May 20, 2010

Vasile, E., Caponi, S., Lucchesi, M., Del Chiaro, M., Funel, N., Ginocchi, L., Campani, D., Falcone, A., Boggi, U., & Mosca, F. (2010). Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Journal of Clinical Oncology, 28(15_suppl), e14605–e14605. https://doi.org/10.1200/jco.2010.28.15_suppl.e14605

Pancreas / Apr 01, 2019

Baretti, M., Pulluri, B., Tsai, H.-L., Blackford, A. L., Wolfgang, C. L., Laheru, D., Zheng, L., Herman, J., Le, D. T., Narang, A. K., & de Jesus-Acosta, A. (2019). The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas, 48(4), 585–589. https://doi.org/10.1097/mpa.0000000000001262

Clinical Colorectal Cancer / Sep 01, 2018

Baretti, M., Rimassa, L., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., & Santoro, A. (2018). Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 17(3), e489–e498. https://doi.org/10.1016/j.clcc.2018.03.010

Cancer Biology & Therapy / Apr 13, 2018

Baretti, M., Personeni, N., Destro, A., Santoro, A., & Rimassa, L. (2018). Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biology &amp; Therapy, 19(8), 659–663. https://doi.org/10.1080/15384047.2018.1450117

Gastric Cancer / Aug 16, 2016

Personeni, N., Baretti, M., Bozzarelli, S., Spaggiari, P., Rubino, L., Tronconi, M. C., Fumagalli Romario, U., Rosati, R., Giordano, L., Roncalli, M., Santoro, A., & Rimassa, L. (2016). Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 20(3), 428–437. https://doi.org/10.1007/s10120-016-0625-1

Lung Cancer / May 01, 2016

Metro, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Mountzios, G., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., & Toschi, L. (2016). Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 95, 82–87. https://doi.org/10.1016/j.lungcan.2016.03.006